Date: 2017-06-21
Type of information: Opening of new premises
Compound: Lilly Biotechnology Center in San Diego
Company: Eli Lilly (USA - IN)
Therapeutic area:
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On June 21, 2017, Eli Lilly announced completion of a $90 million expansion of its Biotechnology Center in San Diego. Lilly's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the emerging area of pain. The center features a new technologically-advanced laboratory and an additional 180,000 square feet of working space, which is an increase of 145 percent compared to the former facility. In addition to the center's established presence in preclinical and clinical immunology research, the new space allows for closer partnership between Lilly experts in biotechnology, discovery chemistry and research technologies while also fostering external collaborations.
- As a pioneer in automated organic synthesis, Lilly is creating the Lilly Life Science Studio in San Diego. Building upon Lilly's Automated Synthesis Laboratory in Indianapolis, the new facility will allow researchers across the globe to remotely design, synthesize and screen investigational molecules in an unprecedented manner. Using the power of automation, the Lilly Life Sciences Studio will shape the next generation of drug discovery and expand the reach of individual scientists to test new ideas, while reducing the cost and minimizing the environmental impact of our research activities.
- In 2017, Lilly plans to spend approximately $5 billion on global R&D, nearly $4 billion of which will be invested in U.S. based programs, including projects with many of California's leading biomedical research institutions.
- • On July 23, 2015, Eli Lilly revealed plans to expand the Lilly Biotechnology Center located in San Diego, Calif. The expansion will effectively double Lilly's research presence in San Diego as the company seeks to develop new collaborations in one of the world's leading regions for drug research and development. Set to be completed in 2016, the expansion will feature an additional 175,000 square feet of working space and is expected to generate up to 130 potential new job openings, yielding a 140 percent increase in the center\'s space and 70 percent increase in its staff. Importantly, the space will allow for closer collaboration among Lilly experts in discovery chemistry and research technologies and biotechnology, which will help accelerate the discovery of new medicines within the company\'s core therapeutic areas, including immunology.
- The expansion also signifies Lilly's investment in obtaining additional top scientific talent. Specifically, Lilly will be recruiting experts in drug discovery in the disciplines of biotechnology, chemistry and immunology and in immunological clinical development.
- Lilly initially entered the San Diego area in 2004 by acquiring Applied Molecular Evolution, Inc., which now operates as a subsidiary of the company. The Lilly Biotechnology Center was officially established in 2009 and is located near the University of California, San Diego, among other prominent biomedical research institutions.
Financial terms:
Latest news:
Is general: Yes
